Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Zivo Bioscience, Inc. (ZIVO)
|
Add to portfolio |
|
|
|
| Price: |
$2.74
| | Metrics |
| OS: |
10.4
|
M
| |
|
|
| Market cap: |
$28.6
|
M
| |
|
|
|
Net cash:
|
$21.1
|
k
| |
$0.00
|
per share
|
|
EV:
|
$28.6
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($9.7)
|
M
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | -100.0% | | | | | | -100.0% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | 100.0% | | | | | |
| Research and development | 2.2 | 2.1 | 3.8 | 2.3 | 2.8 | 2.4 | 0.8 | 1.0 |
| General and administrative | 6.5 | 6.9 | 4.8 | 4.1 | 1.4 | 2.1 | 0.8 | 2.0 |
| EBIT | -8.7 | -9.1 | -8.6 | -6.4 | -4.2 | -4.5 | -1.6 | -3.1 |
| EBIT margin | | | -42778.4% | | | | | |
| Pre-tax income | -8.7 | -9.2 | -9.1 | -11.5 | -14.6 | -10.0 | -6.1 | -5.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -8.7 | -9.2 | -9.1 | -11.5 | -14.6 | -10.0 | -6.1 | -5.8 |
| Net margin | | | -45528.6% | | | | | |
| |
| Diluted EPS | | ($1.20) | ($1.79) | ($0.04) | ($0.09) | ($0.07) | ($0.05) | ($0.04) |
| Shares outstanding (diluted) | | 7.6 | 5.1 | 276.4 | 156.7 | 139.2 | 133.8 | 130.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|